RxDoctor Payments Data

Jina Miller, MD

Internal Medicine · Shreveport, LANPI 1851337612

Payments from drug & device makers

$1,638in general payments, 2019–2025

Across 105 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$732
  • AstraZeneca$233
  • Lilly USA, LLC$185
  • Novo Nordisk$119
  • UCB, Inc.$115
  • GSK$48
  • plus $207 from 9 others

What the payments were for

  • Food & beverage$1,60698%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,638 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$82,364
Medicare patients
317
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$144,682
JardianceEmpagliflozin89$78,799
EliquisApixaban70$50,795
JanuviaSitagliptin Phosphate22$15,087
TrulicityDulaglutide12$12,784
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,378
Losartan Potassium457$4,903
Levothyroxine Sodium598$4,598
Rosuvastatin Calcium291$3,759
Dexlansoprazole DrDexlansoprazole14$3,516
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,445
SynthroidLevothyroxine Sodium73$3,336
Gabapentin225$2,748
Amlodipine Besylate493$2,591
Vilazodone Hcl19$2,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$144,682109 claims
Boehringer IngelheimJardiance$15$78,79989 claims
PfizerEliquis$47$50,79570 claims
Lilly USA, LLCTrulicity$185$12,78412 claims
AbbVieSynthroid$732$3,33673 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →